Anticipating Revvity's Earnings Report
Revvity (NYSE:RVTY) is gearing up for its upcoming quarterly earnings report, which is always a highly awaited event amongst investors. As the earnings date approaches, it is essential for shareholders and potential investors alike to understand what to expect. Analysts are predicting that Revvity will announce an earnings per share (EPS) of $1.14, a figure that many will be watching closely.
What Investors Want to Hear
The hope amongst Revvity supporters is that not only will the company surpass the EPS estimate, but they will also issue optimistic guidance for the near future. Guidance can be one of the most crucial factors influencing investor sentiment, often playing a more significant role than the reported earnings themselves.
Looking Back at Previous Earnings
Referring to previous performance can provide insights into how the stock may react following the earnings announcement. In the past quarter, Revvity managed to beat their EPS estimate by $0.04. Despite this positive surprise, the share price fell by 0.6% the day after the announcement, showing how stock reactions can sometimes defy predictions.
Recent Past EPS Performance
Here’s a summary of Revvity's historical performance compared to expectations:
- Q2 2025 - EPS Estimate: $1.14, EPS Actual: $1.18
- Q1 2025 - EPS Estimate: $0.95, EPS Actual: $1.01
- Q4 2024 - EPS Estimate: $1.38, EPS Actual: $1.42
- Q3 2024 - EPS Estimate: $1.13, EPS Actual: $1.28
The fluctuations in share prices following these announcements indicate a complex relationship between analyst expectations and market reactions.
Revvity's Stock Market Performance
As of late October, Revvity's shares were trading at $97.57, marking a decline of 15.58% over the past year. With overall negative trends, long-term investors may be feeling cautious ahead of the earnings report.
Market Sentiments and Analyst Ratings
Keeping a finger on the pulse of market sentiments and assessments from analysts can greatly benefit investors. Currently, Revvity holds a consensus rating of Outperform, with five analysts weighing in on the stock. The average target price prediction is $106.00, representing an expected rise of approximately 8.64% over the next year.
How Revvity Compares to Peers
It’s also beneficial for investors to view Revvity in the context of its peers. Comparing its ratings to other companies within the same industry may offer valuable insights into market positioning. For instance:
- Qiagen is currently rated Neutral with an average price target suggesting a possible decline of 47.22%.
- Avantor has a rating of Outperform, yet its forecast hints at a higher downside risk of 84.63%.
- Bio-Techne holds a Buy recommendation, suggesting moderate downside of 29.08%.
Analyzing Revvity's Financial Metrics
Let’s dive deeper into Revvity’s financial metrics as they could reflect the company's operational health:
- Revenue Growth: For the latest reporting period, Revvity reported a revenue growth of 4.13%.
- Net Margin: The company's net margin is impressive at 7.49%, showcasing solid profitability.
- Return on Equity (ROE): Revvity's ROE stands at 0.71%, which indicates some challenges in efficiently using equity capital.
- Return on Assets (ROA): The company has a ROA of 0.44%, suggesting inefficiencies in asset utilization.
- Debt Management: Revvity's debt-to-equity ratio is favorable at 0.45.
Understanding Revvity's Position
Revvity is a player well-positioned within the global life sciences and diagnostics sectors, which has become increasingly significant since its rebranding from PerkinElmer. The company operates in life sciences, diagnostics, and offers software solutions targeting biopharma and academic research needs.
Frequently Asked Questions
What will Revvity report in their upcoming earnings?
Analysts estimate Revvity will report an earnings per share (EPS) of $1.14.
How did Revvity perform in the past quarter?
Last quarter, Revvity beat the EPS estimate by $0.04 but saw its share price decrease by 0.6% afterward.
What is Revvity's current stock price?
As of October 23, Revvity's shares were trading at $97.57.
How does Revvity rank compared to its peers?
Revvity ranks well in gross profit but shows room for growth in revenue-related metrics compared to peers.
What segments does Revvity operate in?
The company operates in life sciences and diagnostics, providing various services and products globally.
